GSA Capital Partners LLP Takes Position in Actinium Pharmaceuticals Inc. (ATNM)
GSA Capital Partners LLP bought a new position in Actinium Pharmaceuticals Inc. (NYSEMKT:ATNM) during the second quarter, Holdings Channel reports. The fund bought 139,400 shares of the company’s stock, valued at approximately $247,000. GSA Capital Partners LLP owned 0.30% of Actinium Pharmaceuticals at the end of the most recent reporting period.
Shares of Actinium Pharmaceuticals Inc. (NYSEMKT:ATNM) traded up 0.75% during mid-day trading on Friday, reaching $1.34. 1,115,730 shares of the company traded hands. Actinium Pharmaceuticals Inc. has a 52-week low of $1.29 and a 52-week high of $3.50. The company’s 50 day moving average is $1.71 and its 200 day moving average is $1.81. The stock’s market capitalization is $63.94 million.
Several equities analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a report on Monday, June 6th. FBR & Co reissued a “buy” rating on shares of Actinium Pharmaceuticals in a research note on Thursday, June 30th. Roth Capital reissued a “buy” rating and issued a $5.00 price target on shares of Actinium Pharmaceuticals in a research note on Wednesday. Finally, HC Wainwright reissued a “buy” rating on shares of Actinium Pharmaceuticals in a research note on Thursday, June 2nd.
In other news, major shareholder Sloan-Kettering Cance Memorial sold 20,840 shares of the firm’s stock in a transaction on Wednesday, July 6th. The stock was sold at an average price of $1.81, for a total value of $37,720.40. Following the completion of the transaction, the insider now owns 5,001,886 shares in the company, valued at $9,053,413.66. The sale was disclosed in a document filed with the SEC, which is available at this link.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Want to see what other hedge funds are holding ATNM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Actinium Pharmaceuticals Inc. (NYSEMKT:ATNM).
Receive News & Ratings for Actinium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.